United States
Print page content Print
Increase text size Decrease text size
Text Size
CYTOPOINT is now approved for the treatment of allergic dermatitis! Learn more
Cytopoint logo

This site is intended for U.S.
animal healthcare professionals

Before Treatment

After Cytopoint

CYTOPOINT® can reduce itch to help restore quality of life for dogs–and owners1

Veterinarian: Dr Liz Hardesty, Murrayhill Veterinary Hospital, Beaverton, OR

Sophie’s chronic canine atopic dermatitis forced her to stop her work as a therapy dog

Presentation and history

Sophie is a trained therapy dog. She and her owner thrived on their twice-weekly visits to a local nursing home, where Sophie engaged with and comforted the residents. Shortly after she turned 2, Sophie developed severe itching focused on her ears. Her feet became inflamed, and she developed hot spots. Several food trials were tried but did not improve Sophie’s condition, and Dr Hardesty diagnosed Sophie with canine atopic dermatitis.

Owner's perspective

Her diminished energy and hot spots led her owner to reluctantly cancel their regular nursing home visits. In addition, Sophie’s owner wasn’t always able to comply with her medication schedules, and disliked putting ointments on Sophie’s skin.

“When Sophie was bothered by allergies, it was exhausting for her to scratch and to bite. And the quality of her life went from just an exuberant puppy to a young dog with some real issues.”
— Rick Sirianni, 6/21/16

Sophie Golden Retriever With Chronic Canine Atopic Dermatitis

Sophie is back to her old self and has returned to her therapy rounds

Treatment decision

Dr Hardesty began treating Sophie with APOQUEL® (oclactinib tablet) to manage her atopic dermatitis, with very good results. As soon as Dr Hardesty had access to the new monoclonal antibody therapy (mAb), CYTOPOINT, she switched Sophie to monthly CYTOPOINT injections to make compliance easier for Sophie’s owner.

CYTOPOINT Treatment result

After her first CYTOPOINT treatment, Sophie’s condition improved rapidly. Dr Hardesty noted, “it was so nice to do a [1-month] recheck for Sophie and not see some hint of otitis, pododermatitis, or itchiness.”

Sophie has now been receiving CYTOPOINT for approximately 6 months, and continues to do very well. Dr Hardesty reports that seeing Sophie monthly for injections has provided a valuable point of regular contact with Sophie and her owner, allowing her to keep a close eye on Sophie’s overall health.

“When I hurt, she hurts and when she hurts, I hurt. So to see her be pain free and not irritated...has been a profound relief for me. It’s a comfort to know that those days are behind her.”
— Rick Sirianni, 6/21/16

Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

APOQUEL Indications: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

IMPORTANT SAFETY INFORMATION: Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines. For more information, please see the full Prescribing Information.